Related Experiment Video
Updated: Jun 29, 2025
13:51
Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
9.9K
RhoA/ROCK Pathway Is Upregulated in Experimental Autoimmune Myocarditis and Is Inhibited by Simvastatin at the Stage
Monika Skrzypiec-Spring1, Maciej Kaczorowski2, Alina Rak-Pasikowska3
1Department of Pharmacology, Wroclaw Medical University, 50-345 Wroclaw, Poland.
Biomedicines
|March 28, 2024
Summary
Simvastatin targets the RhoA/ROCK pathway in autoimmune myocarditis by inhibiting myosin light chain phosphorylation. This study offers new insights into the molecular pathology of this cardiovascular disease.
Area of Science:
- Cardiovascular Research
- Immunology
- Molecular Pathology
Background:
- The RhoA/ROCK pathway is implicated in autoimmune and cardiovascular diseases.
- Downregulation of this pathway has shown beneficial effects.
- Simvastatin's effects on autoimmune myocarditis (EAM) require further investigation regarding its molecular targets.
Purpose of the Study:
- To investigate if simvastatin targets the RhoA/ROCK pathway in experimental autoimmune myocarditis.
- To determine if MMP-9 downregulation is linked to MLC phosphorylation.
- To elucidate the molecular mechanisms of simvastatin's action in EAM.
Main Methods:
- Experimental autoimmune myocarditis induced in rats.
- Simvastatin administered via gastric gavage for 3 weeks.
- Immunohistochemical staining for RhoA and ROCK1.
- Western blotting for phosphorylated myosin light chain (phospho-MYL9).
Main Results:
- ROCK1 expression was significantly upregulated in EAM hearts, unaffected by simvastatin.
- RhoA expression showed no significant difference between groups.
- Simvastatin, at the highest dose, prevented the increase in phospho-MYL9 in EAM hearts.
Conclusions:
- The RhoA/ROCK pathway is upregulated in experimental autoimmune myocarditis.
- Simvastatin inhibits the RhoA/ROCK pathway at the myosin light chain phosphorylation stage in EAM.
- This study provides novel insights into the molecular pathology of autoimmune myocarditis.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K